全文获取类型
收费全文 | 1859篇 |
免费 | 109篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 43篇 |
妇产科学 | 36篇 |
基础医学 | 178篇 |
口腔科学 | 15篇 |
临床医学 | 131篇 |
内科学 | 393篇 |
皮肤病学 | 26篇 |
神经病学 | 128篇 |
特种医学 | 63篇 |
外科学 | 340篇 |
综合类 | 2篇 |
预防医学 | 68篇 |
眼科学 | 86篇 |
药学 | 220篇 |
中国医学 | 52篇 |
肿瘤学 | 161篇 |
出版年
2023年 | 13篇 |
2022年 | 35篇 |
2021年 | 57篇 |
2020年 | 33篇 |
2019年 | 43篇 |
2018年 | 56篇 |
2017年 | 45篇 |
2016年 | 24篇 |
2015年 | 45篇 |
2014年 | 77篇 |
2013年 | 88篇 |
2012年 | 129篇 |
2011年 | 139篇 |
2010年 | 67篇 |
2009年 | 72篇 |
2008年 | 115篇 |
2007年 | 88篇 |
2006年 | 104篇 |
2005年 | 98篇 |
2004年 | 96篇 |
2003年 | 100篇 |
2002年 | 84篇 |
2001年 | 34篇 |
2000年 | 28篇 |
1999年 | 29篇 |
1998年 | 17篇 |
1997年 | 20篇 |
1996年 | 13篇 |
1995年 | 5篇 |
1994年 | 13篇 |
1993年 | 7篇 |
1992年 | 29篇 |
1991年 | 26篇 |
1990年 | 20篇 |
1989年 | 16篇 |
1988年 | 12篇 |
1987年 | 14篇 |
1986年 | 13篇 |
1985年 | 13篇 |
1984年 | 9篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 10篇 |
1972年 | 2篇 |
1937年 | 1篇 |
1914年 | 1篇 |
排序方式: 共有1972条查询结果,搜索用时 321 毫秒
41.
Salvatore De Rosa Francesca Eposito Cristina Carella Antonio Strangio Giuseppe Ammirati Jolanda Sabatino Fabio Giovanni Abbate Claudio Iaconetti Vincenzo Liguori Valerio Pergola Alberto Polimeni Silvio Coletta Clarice Gareri Bruno Trimarco Giuseppe Stabile Antonio Curcio Ciro Indolfi Antonio Rapacciuolo 《European journal of heart failure》2018,20(6):1000-1010
Aims
Circulating levels of microRNAs (miRNAs) are emergent promising biomarkers for cardiovascular disease. Altered expression of miRNAs has been related to heart failure (HF) and cardiac remodelling. We measured the concentration gradients across the coronary circulation to assess their usefulness to diagnose HF of different aetiologies.Methods and results
Circulating miRNAs were measured in plasma samples simultaneously obtained from the aorta and the coronary venous sinus in patients with non‐ischaemic HF (NICM‐HF, n = 23) ischaemic HF (ICM‐HF, n = 41), and in control patients (n = 11). A differential modulation of circulating levels of miR‐423, ‐34a, ‐21‐3p, ‐126, ‐199 and ‐30a was found across the aetiology groups. Interestingly, a positive transcoronary gradient was found for miR‐423 (P < 0.001) and miR‐34a (P < 0.001) only in the ICM‐HF group. On the contrary, a positive gradient was found for miR‐21‐3p (P < 0.001) and miR‐30a (P = 0.030) only in the NICM‐HF group. Finally, no significant variations were observed in the transcoronary gradient of miR‐126 or miR‐199.Conclusions
The present findings suggest that circulating levels of miRNAs are differentially expressed in patients with HF of different aetiologies. The presence of a transcoronary concentration gradient suggests a selective release of miRNAs by the failing heart into the coronary circulation. The presence of aetiology‐specific transcoronary concentration gradients in HF patients might provide important information to better understand their role in HF, and suggests they could be useful biomarkers to distinguish HF of different aetiologies.42.
Primary cardiac T-cell lymphoma 总被引:1,自引:0,他引:1
Giunta R Cravero RG Granata G Sellitto A Romano C De Fanis U Foccillo G De Capite C Santini M Rossiello L Rossiello R Lucivero G 《Annals of hematology》2004,83(7):450-454
Primary cardiac lymphoma (PCL), defined as a lymphoma clinically mimicking cardiac disease, with the bulk of the tumor located intrapericardially, is extremely rare in immunocompetent patients. Clinical manifestations vary depending on sites of involvement in the heart and include chest pain, arrhythmias, pericardial effusion, and heart failure. Diagnosis is often difficult and may require invasive procedures; in some cases, diagnosis is not made until autopsy. Histologically, nearly all cases of PCL reported thus far have been of B-cell origin. In this report, we describe a case of PCL of T-cell origin in an adult immunocompetent patient, the second reported in the literature to the best of our knowledge, and provide a brief overview of the features of previously published PCL cases. 相似文献
43.
Galizia G Ferraraccio F Lieto E Orditura M Castellano P Imperatore V Romano C Vollaro M Agostini B Pignatelli C De Vita F 《Diseases of the colon and rectum》2004,47(11):1904-1914
PURPOSE Early-stage colon cancer patients (Dukes A or B; pT1–T3 pNO pMO) are excluded from adjuvant chemotherapy following potentially curative surgery because they are expected to have good long-term survival. However, 20 percent to 30 percent of these patients ultimately succumb from recurrent disease. This indicates that the conventional staging procedures may be unable to precisely predict cancer prognosis.METHODS In 65 early-stage colon cancers, we investigated by immunohistochemistry the role of molecular markers such as p27, p53, and vascular endothelial growth factor in identifying high-risk patients who may benefit from adjuvant treatments.RESULTS No clinicopathologic factor, namely Dukes stage, t parameter, number of resected nodes, and vascular or lymphatic invasion, was found be an independent significant predictor of disease-specific and disease-free survival. In contrast, each molecular marker predicted survival and recurrence rates much better than the conventional Dukes staging system. The best combination of variables for prediction of long-term outcome and recurrence rate included p27, p53, and vascular endothelial growth factor. Interestingly, the greater the number of molecular alterations, the lower the five-year estimated survival function. Nearly all cancer-related deaths were observed among patients whose colon cancers expressed all three molecular alterations. Regardless of Dukes stage, the recurrence rate was found to increase with the increase in the number of molecular alterations. Early-stage colon cancers expressing p27 down-regulation and high p53 and vascular endothelial growth factor immunoreactivity showed a 100 percent actuarial four-year recurrence rate.CONCLUSIONS Assessment of molecular alterations may be useful to identify a higher-risk group of early-stage colon cancer patients who may benefit from adjuvant chemotherapy. 相似文献
44.
Nuzzo F Morabito A De Maio E Di Rella F Gravina A Labonia V Landi G Pacilio C Piccirillo MC Rossi E D'Aiuto G Thomas R Gori S Colozza M De Placido S Lauria R Signoriello G Gallo C Perrone F de Matteis A 《Critical reviews in oncology/hematology》2008,66(2):171-180
Within an ongoing multicentre phase 3 randomised trial (ELDA, cancertrials.gov ID: NCT00331097), early breast cancer patients, 65-79 years old, with average to high risk of recurrence, are randomly assigned to receive CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1-8) or docetaxel (35 mg/m2 days 1-8-15), every 4 weeks. Here we report an unplanned safety analysis prompted by an amendment introducing creatinine clearance as a tool to adjust methotrexate dose. Before such change, 101 patients with a median age of 70 were randomly assigned CMF (53 patients) or docetaxel (48 patients). At least one grades 3-4 toxic event of any type was reported in 40 (75.5%) and 19 (39.6%) patients with CMF and docetaxel, respectively (p=0.0002). Grades 3-4 hematological events were observed in 37 (69.8%) vs. 4 (8.3%) cases (p<0.0001) and grades 3-4 non-hematological toxicity in 12 (22.6%) vs. 15 (31.2%) patients (p=0.11), with CMF and docetaxel, respectively. A higher incidence of anemia, neutropenia, thrombocytopenia and febrile neutropenia was reported with CMF. Constipation, mucositis, nausea and vomiting were more common with CMF; diarrhoea, abdominal pain, dysgeusia, neuropathy and liver toxicity were more frequent with docetaxel. No significant interaction was found between the occurrence of severe toxicity and baseline variables, including creatinine clearance and geriatric activity scales. In conclusion, weekly docetaxel appears to be less toxic than CMF in terms of hematological toxicity. 相似文献
45.
Cancer and stromal cells, which include (cancer‐associated) fibroblasts, adipocytes, and immune cells, constitute a mixed cellular ecosystem that dynamically influences the behavior of each component, creating conditions that ultimately favor the emergence of malignant clones. Ovarian cancer cells release cytokines that recruit and activate stromal fibroblasts and immune cells, so perpetuating a state of inflammation in the stroma that hampers the immune response and facilitates cancer survival and propagation. Further, the stroma vasculature impacts the metabolism of the cells by providing or limiting the availability of oxygen and nutrients. Autophagy, a lysosomal catabolic process with homeostatic and prosurvival functions, influences the behavior of cancer cells, affecting a variety of processes such as the survival in metabolic harsh conditions, the invasive growth, the development of immune and chemo resistance, the maintenance of stem‐like properties, and dormancy. Further, autophagy is involved in the secretion and the signaling of promigratory cytokines. Cancer‐associated fibroblasts can influence the actual level of autophagy in ovarian cancer cells through the secretion of pro‐inflammatory cytokines and the release of autophagy‐derived metabolites and substrates. Interrupting the metabolic cross‐talk between cancer cells and cancer‐associated fibroblasts could be an effective therapeutic strategy to arrest the progression and prevent the relapse of ovarian cancer. 相似文献
46.
Karthikeyan Arcot Sadagopan Robert Battista Rosanne B. Keep Jenina E. Capasso 《Ophthalmic genetics》2015,36(2):156-159
Background: Leber congenital amaurosis (LCA) is most often an autosomal recessive disorder. We report a father and son with autosomal dominant LCA due to a mutation in the CRX gene.
Materials and Methods: DNA screening using an allele specific assay of 90 of the most common LCA-causing variations in the coding sequences of AIPL1, CEP290, CRB1, CRX, GUCY2D, RDH12 and RPE65 was performed on the father. Automated DNA sequencing of his son examining exon 3 of the CRX gene was subsequently performed.
Results: Both father and son have a heterozygous single base pair deletion of an adenine at codon 153 in the coding sequence of the CRX gene resulting in a frameshift mutation.
Conclusion: Mutations involving the CRX gene may demonstrate an autosomal dominant inheritance pattern for LCA. 相似文献
47.
48.
Adriano N. Kochi MD MSc Massimo Moltrasio MD Fabrizio Tundo MD PhD Stefania Riva MD Ciro Ascione MD Maria A. Dessanai MD Francesca Pizzamiglio MD Giulia Vettor MD Selene Cellucci CCP Alessio Gasperetti MD Claudio Tondo MD PhD Gaetano Fassini MD 《Journal of cardiovascular electrophysiology》2021,32(3):588-594
49.
Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. 总被引:1,自引:0,他引:1
Antonio Coppola Ciro De Simone Nicola Macarone Palmieri Daniela Coppola Francesco Lanza Carlo Ruosi Aldo Amoriello Giovanni Di Minno 《Blood coagulation & fibrinolysis》2007,18(2):199-201
Over the past 10 years recombinant activated factor VIIa (rFVIIa) has been successfully used for treatment and prophylaxis of bleeding in patients with platelet defects, including thrombocytopenia and congenital and acquired platelet function abnormalities. Most reported data concern patients with Glanzmann's thrombasthenia and the information available is still limited, especially for surgery. We report on a 15-year-old girl with thrombocytopenia ( approximately 60,000/microl) and platelet dysfunction (bleeding time 30 min, absent platelet aggregation and ATP secretion in response to collagen), related to thrombocytopenia with absent radii syndrome, undergoing two surgical interventions on the upper limbs due to forearm deformities, with prolonged postoperative revisions. In both surgeries rFVIIa was successfully employed as a bolus administration (80 microg/kg every 4 h during the first day, then every 6 h over the following 5 and 3 days, respectively; tranexamic acid was associated from the second day, administered for 2 weeks), avoiding the need for blood products. This report highlights rFVIIa as an attractive, alternative approach to secure hemostasis in patients with platelet defects; on the other hand, the heterogeneity of reported rFVIIa treatment regimens and, in particular, the lack of definite and easily available parameters (or assays) for monitoring rFVIIa efficacy and safety are the main open issues in this setting. 相似文献
50.
G Capasso D Tepper J M Capasso E H Sonnenblick 《The American journal of the medical sciences》1986,291(4):232-240
The mechanical and electrical effects of hypoparathyroidism (Px), hypothyroidism (Tx), and hypothyroidism combined with hypoparathyroidism (TPx) were investigated by comparing simultaneously recorded transmembrane action potentials and isometric and isotonic contractions recorded from the myocardium. Left ventricular papillary muscles from male Wistar rats were studied electrically and mechanically in a muscle bath at 30 degree C, stimulated at 0.1 Hz and external calcium = 2.4 mM. No significant difference was found between control (C), Px, Tx, and TPx preparations with regard to resting tension and developed tension. However, time to peak tension, time to one half relaxation and time to peak shortening were significantly increased in preparations from animals that were Px, Tx, and TPx as compared with age-matched controls. Maximum velocities of shortening (Vs) and relengthening (Vr) at all relative loads studied were significantly depressed in Px preparations when compared with those of C muscles. A greater depression was found in the Tx muscle and still greater depression of these indices was noted in TPx muscles. No significant difference was found between C, Px, Tx, and TPx action potential with regard to resting membrane potential (RMP), action potential amplitude (AMP), overshoot (OS), or maximum rate of rise of the upstroke (Vmax).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献